Sutro strengthens its immuno-oncology pipeline with two new ADCs
ASCOLicense out/inPhase 1Vaccine
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Preview
Source: Pharmaceutical Technology
Sutro generated $772m in partnership payments as of 30 June 2023. Image Credit: Plufflyman / Shutterstock.
Sutro Biopharma plans to submit investigational new drug (IND) applications for its two antibody-drug conjugates (ADCs), STRO-003 and STRO-004, in Q1 2024 and Q1 2025, respectively.
STRO-003 is an ADC that targets ROR1-expressing tumourROR1-expressing tumour cells to cause DNA disruption. As per pre-clinical data, STRO-003 showed anti-tumour activity in non-small cell lung cancer (NSCLC) and breast cancer models. It also showed a potential to augment checkpoint inhibitors therapy.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Vaccine To Target Brachyury For Oncology in Solid Tumor GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Vaccine To Target Brachyury For Oncology in Merkel Cell Carcinoma GlobalData
View allCompanies IntelligenceMerck KGaASutro Biopharma IncVaxcyte IncAmerican Society of Clinical OncologyBionova SLView all
This pre-clinical data was first presented in April 2023 at the annual American Association for Cancer Research (AACR) meeting.
According to the company’s press release, Sutro generated $772m in partnership payments as of 30 June 2023. Most of the payments were generated from partnerships for its cell-free platform for drug design and manufacture. The partnership agreements for Sutro’s cell-free platform include drug design partnerships with Astellas and VaxcyteVaxcyte. Along with manufacturing deals with Merck (MSD) and BioNova for MK-1484 and BN301 (STRO-001), respectively.
Clinical pipeline update
Luventa (luventamab tazevibulin; STRO-002) is an ADC that targets folate receptor alpha (FolRα).
Sutro initiated a registration-directed Phase II/III trial for Luventa in patients with platinum-resistant ovarian cancer. The company will apply for either accelerated approval based on the overall response rate (ORR) once data from about 110 patients has been analysed or a full approval based on progression-free survival (PFS) at the end of the trial.
The data from the open-label Phase I trial (NCT03748186) for Luventa was presented in June 2023 at the annual American Society of Clinical Oncology (ASCO) meeting. Additional updated data from the study will be released by the end of 2023.
Sutro also plans to initiate a pivotal or registration-enabling protocol for Luventa’s approval in the paediatric population with a rare subtype of acute myeloid leukaemia (AML), CBFA2T3-GLIS2 positive AMLCBFA2T3-GLIS2 positive AML. This follows positive results from the compassionate use of Luventa presented at the American Society of Haematology Annual Meeting and Exposition (ASH 2022).
Luventa is also being investigated as a combination therapy with bevacizumab in advanced ovarian cancer and endometrial cancer.
STRO-001 is an ADC that targets CD74. It is being investigated in Phase I trials in Greater China by BioNova for non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.